Based on these advantages, this technology has the potential to be applied to the drug discovery for some neurodegenerative diseases related to the MC-I activity such as ischemic stroke and Alzheimer’s disease. This evidence concerns the gene MCIDAS and early-onset autosomal dominant Alzheimer disease.